Login to Your Account

Celgene's Apremilast Looks Positive in Top-Line PsA Data

By Marie Powers
Staff Writer

Friday, July 13, 2012

Celgene International Sàrl, the Boudry, Switzerland, subsidiary of Celgene Corp., reported positive top-line results for apremilast, an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), in patients with psoriatic arthritis (PsA) who had received an oral disease-modifying antirheumatic drug (DMARD) or biologic therapy or had failed on an anti-tumor necrosis factor (TNF) agent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription